KR100861415B1 - Method of preparing cosmetics composition and cosmetics for anti-oxidation and skin-calming, prepared therefrom - Google Patents
Method of preparing cosmetics composition and cosmetics for anti-oxidation and skin-calming, prepared therefrom Download PDFInfo
- Publication number
- KR100861415B1 KR100861415B1 KR1020070041426A KR20070041426A KR100861415B1 KR 100861415 B1 KR100861415 B1 KR 100861415B1 KR 1020070041426 A KR1020070041426 A KR 1020070041426A KR 20070041426 A KR20070041426 A KR 20070041426A KR 100861415 B1 KR100861415 B1 KR 100861415B1
- Authority
- KR
- South Korea
- Prior art keywords
- cosmetic composition
- weight
- parts
- skin
- present
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 83
- 239000002537 cosmetic Substances 0.000 title claims abstract description 66
- 238000000034 method Methods 0.000 title claims abstract description 19
- 230000003064 anti-oxidating effect Effects 0.000 title abstract description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 31
- 239000000284 extract Substances 0.000 claims abstract description 18
- 240000007311 Commiphora myrrha Species 0.000 claims abstract description 9
- 235000006965 Commiphora myrrha Nutrition 0.000 claims abstract description 8
- 235000007265 Myrrhis odorata Nutrition 0.000 claims abstract description 8
- 230000003385 bacteriostatic effect Effects 0.000 claims abstract description 8
- 238000002156 mixing Methods 0.000 claims abstract description 8
- 230000002849 elastaseinhibitory effect Effects 0.000 claims abstract description 3
- 229920001661 Chitosan Polymers 0.000 claims description 17
- 230000003078 antioxidant effect Effects 0.000 claims description 12
- 235000013336 milk Nutrition 0.000 claims description 9
- 239000008267 milk Substances 0.000 claims description 9
- 210000004080 milk Anatomy 0.000 claims description 9
- 238000001816 cooling Methods 0.000 claims description 5
- 238000004821 distillation Methods 0.000 claims description 4
- 238000003809 water extraction Methods 0.000 claims description 4
- 241000208340 Araliaceae Species 0.000 claims description 3
- 235000002789 Panax ginseng Nutrition 0.000 claims description 3
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims description 3
- 235000003140 Panax quinquefolius Nutrition 0.000 claims description 3
- 244000305267 Quercus macrolepis Species 0.000 claims description 3
- 235000008434 ginseng Nutrition 0.000 claims description 3
- 241001454694 Clupeiformes Species 0.000 claims description 2
- 235000019513 anchovy Nutrition 0.000 claims description 2
- 244000071378 Viburnum opulus Species 0.000 claims 1
- 235000019013 Viburnum opulus Nutrition 0.000 claims 1
- 206010040880 Skin irritation Diseases 0.000 abstract description 15
- 231100000475 skin irritation Toxicity 0.000 abstract description 15
- 230000036556 skin irritation Effects 0.000 abstract description 15
- 231100000135 cytotoxicity Toxicity 0.000 abstract description 7
- 230000003013 cytotoxicity Effects 0.000 abstract description 7
- 244000061508 Eriobotrya japonica Species 0.000 abstract description 6
- 235000009008 Eriobotrya japonica Nutrition 0.000 abstract description 6
- 241001632410 Eleutherococcus senticosus Species 0.000 abstract description 3
- 244000173853 Sanguisorba officinalis Species 0.000 abstract description 3
- 235000008282 Sanguisorba officinalis Nutrition 0.000 abstract description 3
- 229920001542 oligosaccharide Polymers 0.000 abstract 3
- 241000246044 Sophora flavescens Species 0.000 abstract 2
- 244000131415 Zanthoxylum piperitum Species 0.000 abstract 2
- 235000008853 Zanthoxylum piperitum Nutrition 0.000 abstract 2
- 210000003491 skin Anatomy 0.000 description 36
- 238000012360 testing method Methods 0.000 description 16
- 230000000694 effects Effects 0.000 description 14
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
- 239000003963 antioxidant agent Substances 0.000 description 11
- 235000006708 antioxidants Nutrition 0.000 description 11
- 238000004519 manufacturing process Methods 0.000 description 10
- 241000894006 Bacteria Species 0.000 description 9
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 8
- 241000233866 Fungi Species 0.000 description 7
- 102000016387 Pancreatic elastase Human genes 0.000 description 7
- 108010067372 Pancreatic elastase Proteins 0.000 description 7
- HHEAADYXPMHMCT-UHFFFAOYSA-N dpph Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1[N]N(C=1C=CC=CC=1)C1=CC=CC=C1 HHEAADYXPMHMCT-UHFFFAOYSA-N 0.000 description 7
- 238000000605 extraction Methods 0.000 description 7
- 238000002835 absorbance Methods 0.000 description 6
- 230000009471 action Effects 0.000 description 6
- 230000006378 damage Effects 0.000 description 6
- 210000002510 keratinocyte Anatomy 0.000 description 6
- 230000007774 longterm Effects 0.000 description 6
- 239000006210 lotion Substances 0.000 description 6
- 239000003755 preservative agent Substances 0.000 description 6
- 230000000638 stimulation Effects 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 5
- 230000003110 anti-inflammatory effect Effects 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 239000000049 pigment Substances 0.000 description 5
- 230000003685 thermal hair damage Effects 0.000 description 5
- 229920001817 Agar Polymers 0.000 description 4
- 240000008067 Cucumis sativus Species 0.000 description 4
- ZSBXGIUJOOQZMP-JLNYLFASSA-N Matrine Chemical compound C1CC[C@H]2CN3C(=O)CCC[C@@H]3[C@@H]3[C@H]2N1CCC3 ZSBXGIUJOOQZMP-JLNYLFASSA-N 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 239000008272 agar Substances 0.000 description 4
- -1 amithrin Chemical compound 0.000 description 4
- 239000001569 carbon dioxide Substances 0.000 description 4
- 229910002092 carbon dioxide Inorganic materials 0.000 description 4
- 238000007796 conventional method Methods 0.000 description 4
- 239000003921 oil Substances 0.000 description 4
- 230000003647 oxidation Effects 0.000 description 4
- 238000007254 oxidation reaction Methods 0.000 description 4
- 230000002335 preservative effect Effects 0.000 description 4
- 239000000344 soap Substances 0.000 description 4
- 230000037303 wrinkles Effects 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 208000002874 Acne Vulgaris Diseases 0.000 description 3
- 208000032544 Cicatrix Diseases 0.000 description 3
- 235000010799 Cucumis sativus var sativus Nutrition 0.000 description 3
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- 208000012641 Pigmentation disease Diseases 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 206010000496 acne Diseases 0.000 description 3
- 230000000845 anti-microbial effect Effects 0.000 description 3
- 239000006071 cream Substances 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000012676 herbal extract Substances 0.000 description 3
- 241000411851 herbal medicine Species 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 239000008213 purified water Substances 0.000 description 3
- 231100000241 scar Toxicity 0.000 description 3
- 230000037387 scars Effects 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 235000013599 spices Nutrition 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 230000007704 transition Effects 0.000 description 3
- 208000003322 Coinfection Diseases 0.000 description 2
- 201000004624 Dermatitis Diseases 0.000 description 2
- 229910052691 Erbium Inorganic materials 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- ZSBXGIUJOOQZMP-UHFFFAOYSA-N Isomatrine Natural products C1CCC2CN3C(=O)CCCC3C3C2N1CCC3 ZSBXGIUJOOQZMP-UHFFFAOYSA-N 0.000 description 2
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 2
- 240000001439 Opuntia Species 0.000 description 2
- 235000013389 Opuntia humifusa var. humifusa Nutrition 0.000 description 2
- PSKIOIDCXFHNJA-UHFFFAOYSA-N Sanshool Natural products CC=CC=CC=CCCC=CC=CC(=O)NC(C)C PSKIOIDCXFHNJA-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 231100000263 cytotoxicity test Toxicity 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- UYAHIZSMUZPPFV-UHFFFAOYSA-N erbium Chemical compound [Er] UYAHIZSMUZPPFV-UHFFFAOYSA-N 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 229940074047 glyceryl cocoate Drugs 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000000749 insecticidal effect Effects 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 230000003020 moisturizing effect Effects 0.000 description 2
- 230000019612 pigmentation Effects 0.000 description 2
- 238000007747 plating Methods 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000002062 proliferating effect Effects 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000008929 regeneration Effects 0.000 description 2
- 238000011069 regeneration method Methods 0.000 description 2
- 229930182490 saponin Natural products 0.000 description 2
- 150000007949 saponins Chemical class 0.000 description 2
- 210000004927 skin cell Anatomy 0.000 description 2
- 230000037380 skin damage Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 239000000341 volatile oil Substances 0.000 description 2
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 1
- FFDULTAFAQRACT-NYYYOYJKSA-N (-)-syringaresinol O,O'-bis(beta-D-glucoside) Chemical compound COC1=CC([C@H]2[C@H]3[C@H]([C@@H](OC3)C=3C=C(OC)C(O[C@H]4[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O4)O)=C(OC)C=3)CO2)=CC(OC)=C1O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O FFDULTAFAQRACT-NYYYOYJKSA-N 0.000 description 1
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical group CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- XUCIJNAGGSZNQT-JHSLDZJXSA-N (R)-amygdalin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](O[C@@H](C#N)C=2C=CC=CC=2)O1 XUCIJNAGGSZNQT-JHSLDZJXSA-N 0.000 description 1
- LQIAZOCLNBBZQK-UHFFFAOYSA-N 1-(1,2-Diphosphanylethyl)pyrrolidin-2-one Chemical compound PCC(P)N1CCCC1=O LQIAZOCLNBBZQK-UHFFFAOYSA-N 0.000 description 1
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- BDOYKFSQFYNPKF-UHFFFAOYSA-N 2-[2-[bis(carboxymethyl)amino]ethyl-(carboxymethyl)amino]acetic acid;sodium Chemical compound [Na].[Na].OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O BDOYKFSQFYNPKF-UHFFFAOYSA-N 0.000 description 1
- AZKSAVLVSZKNRD-UHFFFAOYSA-M 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide Chemical compound [Br-].S1C(C)=C(C)N=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=CC=C1 AZKSAVLVSZKNRD-UHFFFAOYSA-M 0.000 description 1
- 241000606750 Actinobacillus Species 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 239000004604 Blowing Agent Substances 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 241000208229 Burseraceae Species 0.000 description 1
- 229920001408 Casuarictin Polymers 0.000 description 1
- 201000006082 Chickenpox Diseases 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 235000009849 Cucumis sativus Nutrition 0.000 description 1
- 241000186427 Cutibacterium acnes Species 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 241000220485 Fabaceae Species 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 102000002274 Matrix Metalloproteinases Human genes 0.000 description 1
- 108010000684 Matrix Metalloproteinases Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 208000005141 Otitis Diseases 0.000 description 1
- 235000019482 Palm oil Nutrition 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 244000243872 Pelargonium tomentosum Species 0.000 description 1
- 235000011265 Pelargonium tomentosum Nutrition 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 241000605861 Prevotella Species 0.000 description 1
- BTRRIKDMBGWCGF-UHFFFAOYSA-N Sanshoamid Natural products CC=CC=CCCC=CC=CC(=O)NCC(C)(C)O BTRRIKDMBGWCGF-UHFFFAOYSA-N 0.000 description 1
- 206010039509 Scab Diseases 0.000 description 1
- 206010039897 Sedation Diseases 0.000 description 1
- 206010059516 Skin toxicity Diseases 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- XRYVAQQLDYTHCL-IQMFZBJNSA-N Sophoraflavanone G Natural products C1([C@H]2CC(=O)C=3C(O)=CC(O)=C(C=3O2)C[C@@H](CC=C(C)C)C(C)=C)=CC=C(O)C=C1O XRYVAQQLDYTHCL-IQMFZBJNSA-N 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 206010046980 Varicella Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 238000001467 acupuncture Methods 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- SBXYHCVXUCYYJT-UEOYEZOQSA-N alpha-Sanshool Chemical compound C\C=C\C=C\C=C/CC\C=C\C(=O)NCC(C)C SBXYHCVXUCYYJT-UEOYEZOQSA-N 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- YZLOSXFCSIDECK-UHFFFAOYSA-N amygdalin Natural products OCC1OC(OCC2OC(O)C(O)C(O)C2O)C(O)C(O)C1OC(C#N)c3ccccc3 YZLOSXFCSIDECK-UHFFFAOYSA-N 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 230000001760 anti-analgesic effect Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000006851 antioxidant defense Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- SBXYHCVXUCYYJT-UMYNZBAMSA-N beta-sanshool Chemical compound C\C=C\C=C\C=C\CC\C=C\C(=O)NCC(C)C SBXYHCVXUCYYJT-UMYNZBAMSA-N 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 230000001914 calming effect Effects 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- WZQCGDLPTFKQNG-NUGBSMSRSA-N chembl507952 Chemical compound OC1=C(O)C(O)=CC(C(=O)O[C@@H]2[C@@H]3OC(=O)C4=CC(O)=C(O)C(O)=C4C4=C(O)C(O)=C(O)C=C4C(=O)O[C@H]3[C@@H]3OC(=O)C4=C(OC=5C(=C(O)C=C(C=5)C(=O)O[C@H]5[C@@H]6OC(=O)C7=CC(O)=C(O)C(O)=C7C7=C(O)C(O)=C(O)C=C7C(=O)O[C@H]6[C@@H]6OC(=O)C7=C(OC=8C(=C(O)C=C(C=8)C(=O)O[C@@H]8[C@@H]9OC(=O)C%10=CC(O)=C(O)C(O)=C%10C%10=C(O)C(O)=C(O)C=C%10C(=O)O[C@H]9[C@@H]9OC(=O)C%10=C(OC=%11C(=C(O)C=C(C=%11)C(=O)O[C@H]%11[C@@H]%12OC(=O)C%13=CC(O)=C(O)C(O)=C%13C%13=C(O)C(O)=C(O)C=C%13C(=O)O[C@H]%12[C@@H]%12OC(=O)C%13=CC(O)=C(O)C(O)=C%13C%13=C(O)C(O)=C(O)C=C%13C(=O)OC[C@H]%12O%11)O)C(O)=C(O)C(O)=C%10C%10=C(O)C(O)=C(O)C=C%10C(=O)OC[C@H]9O8)O)C(O)=C(O)C(O)=C7C7=C(O)C(O)=C(O)C=C7C(=O)OC[C@H]6O5)O)C(O)=C(O)C(O)=C4C4=C(O)C(O)=C(O)C=C4C(=O)OC[C@H]3O2)=C1 WZQCGDLPTFKQNG-NUGBSMSRSA-N 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 229940117173 croton oil Drugs 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 231100000676 disease causative agent Toxicity 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000006353 environmental stress Effects 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 235000019688 fish Nutrition 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 235000020710 ginseng extract Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 229940075529 glyceryl stearate Drugs 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000002439 hemostatic effect Effects 0.000 description 1
- 239000006049 herbal material Substances 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 230000003345 hyperglycaemic effect Effects 0.000 description 1
- 208000000069 hyperpigmentation Diseases 0.000 description 1
- 230000003810 hyperpigmentation Effects 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 238000013095 identification testing Methods 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000002085 irritant Substances 0.000 description 1
- 231100000021 irritant Toxicity 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- USOSNFWVEWONDB-UHFFFAOYSA-N liriodendrin Natural products COc1cc(cc(OC)c1OC2OC(CO)C(O)C(O)C2O)C3OC(C)(C)C4C(OC(C)(C)C34)c5cc(OC)c(OC6OC(CO)C(O)C(O)C6O)c(OC)c5 USOSNFWVEWONDB-UHFFFAOYSA-N 0.000 description 1
- RBLKLJDYAHZCFW-UHFFFAOYSA-L magnesium;2-acetyloxybenzoate Chemical compound [Mg+2].CC(=O)OC1=CC=CC=C1C([O-])=O.CC(=O)OC1=CC=CC=C1C([O-])=O RBLKLJDYAHZCFW-UHFFFAOYSA-L 0.000 description 1
- 239000002075 main ingredient Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 230000002232 neuromuscular Effects 0.000 description 1
- 231100001083 no cytotoxicity Toxicity 0.000 description 1
- 231100000344 non-irritating Toxicity 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 239000002540 palm oil Substances 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 210000004694 pigment cell Anatomy 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 229940055019 propionibacterium acne Drugs 0.000 description 1
- 230000006318 protein oxidation Effects 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 239000011535 reaction buffer Substances 0.000 description 1
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000002207 retinal effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000036280 sedation Effects 0.000 description 1
- 230000009759 skin aging Effects 0.000 description 1
- 231100000430 skin reaction Toxicity 0.000 description 1
- 231100000438 skin toxicity Toxicity 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 229940057950 sodium laureth sulfate Drugs 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- SXHLENDCVBIJFO-UHFFFAOYSA-M sodium;2-[2-(2-dodecoxyethoxy)ethoxy]ethyl sulfate Chemical compound [Na+].CCCCCCCCCCCCOCCOCCOCCOS([O-])(=O)=O SXHLENDCVBIJFO-UHFFFAOYSA-M 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- XRYVAQQLDYTHCL-GMTBNIFVSA-N sophoraflavanone g Chemical compound C1([C@@H]2CC(=O)C=3C(O)=CC(O)=C(C=3O2)CC(CC=C(C)C)C(C)=C)=CC=C(O)C=C1O XRYVAQQLDYTHCL-GMTBNIFVSA-N 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- KOWMJRJXZMEZLD-UHFFFAOYSA-N syringaresinol Chemical compound COC1=C(O)C(OC)=CC(C2C3C(C(OC3)C=3C=C(OC)C(O)=C(OC)C=3)CO2)=C1 KOWMJRJXZMEZLD-UHFFFAOYSA-N 0.000 description 1
- LVUPFEOCDSHRBL-UHFFFAOYSA-N syringaresinol Natural products COc1cccc(OC)c1C2OCC3C2COC3c4c(OC)cccc4OC LVUPFEOCDSHRBL-UHFFFAOYSA-N 0.000 description 1
- 229920001864 tannin Polymers 0.000 description 1
- 239000001648 tannin Substances 0.000 description 1
- 235000018553 tannin Nutrition 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229920003169 water-soluble polymer Polymers 0.000 description 1
- 230000037373 wrinkle formation Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/32—Burseraceae (Frankincense family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/739—Sanguisorba (burnet)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/005—Preparations for sensitive skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medical Informatics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Birds (AREA)
- Dermatology (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Cosmetics (AREA)
Abstract
Description
도 1은 본 발명의 일 실시예에 따라 제조된 화장료 조성물을 인간 유래 각질형성 세포주에 처리하여 MTT 분석한 결과를 나타내는 것이고;Figure 1 shows the results of MTT analysis by treating the cosmetic composition prepared according to an embodiment of the present invention to a human-derived keratinocyte cell line;
도 2는 본 발명의 일 실시예에 따라 제조된 화장료 조성물이 갖는 항산화능을 DPPH를 이용하여 측정한 결과를 나타내는 것이고;Figure 2 shows the results of measuring the antioxidant capacity of the cosmetic composition prepared according to an embodiment of the present invention using DPPH;
도 3은 본 발명의 일 실시예에 따라 제조된 화장료 조성물이 갖는 엘라스타아제 억제 활성을 측정한 결과를 나타내는 것이고;Figure 3 shows the results of measuring the elastase inhibitory activity of the cosmetic composition prepared according to an embodiment of the present invention;
도 4는 본 발명의 일 실시예에 따라 제조된 화장료 조성물이 갖는 정균능을 확인한 결과를 나타내는 것이다.Figure 4 shows the results confirming the bacteriostatic ability of the cosmetic composition prepared according to an embodiment of the present invention.
본 발명은 한방 재료로부터 화장료 조성물을 제조하는 방법에 관한 것이다. The present invention relates to a method for producing a cosmetic composition from herbal materials.
화학적으로 자유라디칼 (free radical)이란 1개 또는 그 이상의 짝짓지 않은 전자를 가진 독립적으로 존재하는 화학종을 말한다. 보통의 분자에서는 스핀의 방향이 반대인 2개의 전자들이 하나의 전자쌍을 만들어 안정한 상태로 존재하나, 이자유라디칼은 짝짓지 않은 활성 전자를 가지고 있기 때문에 일반적으로 불안정하고 이로 인해, 매우 큰 반응성을 가지며 수명이 짧다. Chemically free radicals refer to species that exist independently with one or more unpaired electrons. In ordinary molecules, two electrons with opposite spin directions form a single electron pair and remain stable, but free radicals are generally unstable because they have unpaired active electrons and are therefore highly reactive. Short life
생체 내에서 활성산소의 생성은 다양한 경로를 거쳐서 생성된다. 정상적인 대사과정에 있어서도 호흡한 산소의 2%가 슈퍼옥사이드 라디칼로 전환되는 것으로 알려져 있다. 자외선에 노출 후, 피부 세포 및 조직 손상에 대한 자유라디칼의 원인설은 자외선의 피부 작용에 대한 일관된 손상 기전을 제시하고 있으며, 주요한 생리적 설명은 다음과 같다. The production of free radicals in vivo occurs through a variety of pathways. Even during normal metabolism, 2% of the breathed oxygen is known to be converted to superoxide radicals. The cause of free radicals on skin cell and tissue damage after exposure to UV light suggests a consistent mechanism of damage to the action of UV light. The main physiological explanations are as follows.
(1) 자유라디칼은 피부에 대한 자외선 작용으로 생성된다. (2) 피부에는 자유라디칼을 제거하는 항산화 방어계가 있다. 그러나 이러한 방어계는 자외선량이 많으면 한계에 도달하고 세포 및 조직의 산화가 유발된다. (3) 결과적으로 단백질, 지질, DNA와 같은 주요 세포 성분들은 자유라디칼에 의한 손상을 받게 되어, 세포 기능이 변질되고 궁극적으로는 피부노화가 촉진되어 피부 손상 및 질환이 유발되게 된다.(1) Free radicals are produced by the action of ultraviolet rays on the skin. (2) The skin has an antioxidant defense system that removes free radicals. However, such a defense system reaches its limit when the amount of ultraviolet rays is high and causes oxidation of cells and tissues. (3) As a result, major cellular components such as proteins, lipids, and DNA are damaged by free radicals, resulting in altered cellular function and ultimately promoting skin aging resulting in skin damage and disease.
피부에서 자유라디칼에 의해서 유발되는 주름의 생성 원인은 대표적인 세 가지를 들 수 있다. 첫째, 자외선에 의한 피부 항산화제의 파괴를 들 수 있으며, 둘째, 지질 산화, 단백질 산화, 및 DNA 산화와 같은 세포 구성 성분의 산화 그리고 마지막으로 매트릭스 메탈로프로테나아제 (matrix metalloproteinase) 과발현, 콜 라겐 사슬의 절단과 비정상적인 교차결합, 히아루론산 (hyaluronic acid) 사슬의 절단 등으로 나타나는 결합조직의 손상이다. There are three representative causes of wrinkles caused by free radicals in the skin. First, the destruction of skin antioxidants by UV light; second, the oxidation of cellular components such as lipid oxidation, protein oxidation, and DNA oxidation; and finally matrix metalloproteinase overexpression, collagen. It is a damage to the connective tissue caused by the breakage of chains, abnormal crosslinking, and the breakage of hyaluronic acid chains.
과도한 자외선 노출에 의해 생성된 자유라디칼은 주름 형성을 촉진할 수 있는 다양한 생리적 손상을 유발시킬 뿐만 아니라, 피부에 존재하는 색소 세포를 자극하여 멜라닌 색소의 생성을 가속화시켜 피부를 어둡게 만든다고 알려져 있다. 또한 그 정도와 위치에 따라 심각한 염증 및 피부 면역의 손상을 유발할 수도 있다. Free radicals produced by excessive UV exposure are known to cause various physiological damages that can promote wrinkle formation, as well as to stimulate the pigment cells present in the skin, accelerating the production of melanin pigments and darkening the skin. It can also cause severe inflammation and damage to skin immunity, depending on the extent and location.
최근 들어, 피부에 대한 사람들의 관심이 증가함에 따라 깨끗한 피부를 만들기 위해 피부과에서 레이져 박피 시술을 통한 여드름과 같은 흉터를 치료하는 사례가 늘고 있다. Recently, as people's interest in skin increases, dermatologists are increasingly treating scars such as acne through laser dermabrasion to create clean skin.
레이져 박피는 주로 여드름이나 수두로 인해 발생한 흉터와 주름살 치료에 많이 이용되는데, 치료 원리는 레이져 빛에 의해 피부에 정확하게 1도 화상만을 입혀 진피층에서 새로운 조직들이 많이 자라게 하는 방법이다. 레이저 박피에는 어븀 야그 레이저와 탄산가스 레이저가 사용된다. 탄산가스 레이저는 열 손상이 많아서 치료한 주변 조직에 많은 손상을 입힌다. Laser dermabrasion is mainly used to treat scars and wrinkles caused by acne or chickenpox, and the principle of treatment is a method of growing a lot of new tissues in the dermis by causing only 1 degree burn on the skin by laser light. Erbium yag lasers and carbon dioxide lasers are used for laser dermabrasion. Carbon dioxide lasers have a lot of thermal damage that causes a lot of damage to the surrounding tissues.
어븀야그 레이저는 열손상이 거의 없어서 치료 후에 홍반이나 색소침착 같은 부작용이 탄산가스 레이져에 비해 덜 생긴다. 하지만 반대로 열 손상이 어느 정도 있어야 흉터가 잘 차오른다는 것이 밝혀지면서 최근에는 어븀야그 레이저만으로 치료하기보다는 탄산가스 레이저와 병합해서 사용한다. 한번의 시술로 만족스러운 결과를 얻지 못하는 경우에는 여러 차례 시도하지만, 시술 후의 과색소 침착증 등 부작용도 가지고 있다. 또한 열손상에 의한 피부 화상이 일어날 수 있기 때문에 레이 져 박피 후에는 열손상에 의해 약해진 피부를 진정시키기 위해 자극적이지 않은 진정용 화장수의 사용이 필요하다. Erbium jag lasers have almost no thermal damage, resulting in less side effects such as erythema and pigmentation after treatment than carbon dioxide lasers. On the contrary, as it turns out that the scars can be filled well with some degree of thermal damage, it is recently used in combination with carbon dioxide laser rather than treatment with erb Yag laser alone. If you do not get satisfactory results with a single procedure, try several times, but have side effects such as hyperpigmentation after the procedure. In addition, since skin damage may occur due to thermal damage, the use of a non-irritating soothing lotion is necessary after the laser peeling to soothe the skin weakened by thermal damage.
종래 한방 소재 화장료의 경우 열수(열탕) 추출을 이용하여 추출된 성분을 주 성분으로 함유하고 있는데, 이에 의해서는 유효성분과 함께 손상된 피부를 악화시킬 수 있는 자극 인자도 같이 추출되는 단점이 있어 이를 보완할 수 있는 제조방법의 개발이 필요한 실정이다.Conventional herbal cosmetics contain ingredients extracted using hot water (heated water) extraction as main ingredients, which also have the disadvantage of extracting stimulating factors that can worsen damaged skin along with active ingredients. It is necessary to develop a manufacturing method that can.
본 발명자 등은 이와 같은 문제점을 직시하고, 피부에 자극을 주는 성분이 없이 정제된 상태로 유효성분을 추출하는 방법을 개발하였으며, 이에 따라 제조되는 화장료 조성물이 외부열에 의해 손상되는 피부의 재생을 촉진하고, 항산화능이 우수하며, 장기간 보관에도 미생물의 천이가 생기지 않아 장기간 사용시 피부 자극을 유발하지 않고 피부를 진정시키는 작용이 있음을 확인하고 본 발명을 완성하게 되었다.The present inventors have faced such a problem, and developed a method for extracting the active ingredient in a purified state without the ingredients irritating the skin, thereby promoting the regeneration of the skin is damaged by the external heat of the cosmetic composition prepared In addition, it has excellent anti-oxidant ability, does not cause the transition of microorganisms even in long-term storage, so as to confirm that there is an effect of calming the skin without causing skin irritation during long-term use and completed the present invention.
본 발명의 목적은 피부에 자극을 주는 성분이 없이 정제된 상태로 유효성분을 추출하는 화장료 조성물의 제조방법 및 이에 의해 제조되는 화장료 조성물을 제공하는 것이다.It is an object of the present invention to provide a method for producing a cosmetic composition for extracting an active ingredient in a purified state without the components irritating the skin and a cosmetic composition produced thereby.
상기 목적을 달성하기 위하여, In order to achieve the above object,
본 발명의 일 측면에 따르면, According to one aspect of the invention,
i) 몰약, 지유, 가시오가피, 산초, 비파엽 및 고삼을 혼합하고 물을 가하여 열수추출하는 단계;i) mixing myrrh, fat milk, thorny scab, sancho, non-leafed and ginseng and extracting hot water by adding water;
ii) 상기 단계 i)에서 얻어진 열수추출물을 증류하여 수집하는 단계; 및ii) distilling and collecting the hot water extract obtained in step i); And
iii) 상기 단계 ii)의 수집된 증류액을 키토올리고당과 혼합하는 단계를 포함하는 화장료 조성물의 제조방법을 제시할 수 있다. iii) a method of preparing a cosmetic composition comprising mixing the collected distillate of step ii) with chitooligosaccharides.
이하, 본 발명의 화장료 조성물의 제조에 사용된 6가지의 생약 성분들에 대해 자세히 살펴본다.Hereinafter, the six herbal ingredients used in the preparation of the cosmetic composition of the present invention will be described in detail.
몰약은 Commiphora molmol Engler 또는 기타 동속식물(감람나무과 Burseraceae)에서 얻은 수지이다. 몰약의 정유 성분은 사람의 잇몸 부위의 섬유아세포에 대해서 세포 독성과 항염증 효과를 나타낸다. 수침제(1:2)와 몰약은 각종 피부 진균과 세균의 성장을 억제한다. 몰약은 수렴작용과 진통 작용, 세포재생 효과가 있다. Myrrh Commiphora molmol Resin obtained from Engler or other similar plants ( Olivaceae Burseraceae). Myrrh's essential oils have cytotoxic and anti-inflammatory effects on fibroblasts in human gums. Acupuncture agents (1: 2) and myrrh inhibit the growth of various skin fungi and bacteria. Myrrh has astringent, analgesic, and cell regeneration effects.
지유는 오이풀 (Sanguisorba officinalis L.) 및 동속식물의 뿌리와 뿌리 줄기를 말린 것이다. 냄새는 약하고 맛은 떫으며 조금 쓰다. 지유는 탄닌 성분을 가지고 있는데, 이 성분에 의한 지사 작용을 나타내며 화상 부위의 분비물의 생성을 감소시킨다. 2도 정도의 화상에 오이풀 추출물을 발라주면 2~3일 내에 호전된다. 3도 화성으로 목숨이 위험하다 하더라도 오이풀이나 뿌리를 생즙을 내어 먹이면서 오이풀 추출물을 발라주면 20일 내에 호전된다. 또한 지유의 추출물을 UVB를 조사 한 피부에 발라주면 UVB에 의한 주름생성이나 탄력상실 등으로부터 피부가 보호된다. 또한 피부색소 침착에 관여하는 엔도셀린 전환효소-1α(endothelin-converting enzyme-1α)를 억제함으로써 UVB에 의한 색소 침착을 막는다. 지유의 sanguiin H-11은 항염증 작용을 가지고 있다. 종합적으로 지유의 추출물은 수렴, 지혈작용, 화상, 피부염, 습진 등에 좋은 효과를 가지고 있다.Fat Milk Cucumber ( Sanguisorba officinalis L.) and dried roots and rhizomes of the same plant. The smell is weak, the taste is a little bit bitter. Fat milk has a tannin component, which indicates the fatal action by this component and reduces the production of secretions at the burn site. Applying cucumber extract to burns around 2 degrees improves in 2-3 days. Even if the life is dangerous to Mars 3 degrees, if you apply cucumber extracts while feeding the cucumbers or roots with fresh juice, it will improve within 20 days. In addition, applying oil extract to the skin irradiated with UVB protects the skin from UVB wrinkles and loss of elasticity. It also prevents pigmentation by UVB by inhibiting endothelin-converting enzyme-1α, which is involved in skin pigmentation. Fat milk sanguiin H-11 has anti-inflammatory action. Overall, the extract of fat milk has a good effect on astringent, hemostatic action, burns, dermatitis, eczema.
가시오가피는 가시오가피나무 Acanthopanax senticosus Maxim(오갈피나무과 Araliaceae)의 뿌리 및 뿌리줄기를 건조한 것이다. 가시오가피의 주된 효과는 사포닌 성분의 강장 작용이다. 사포닌 성분은 심근경색을 예방하며, 고혈당증 동물에서 혈당강하작용을 나타낸다. 가시오가피의 추출물은 피부과민성(mast cell-dependent anaphylaxis)과 히스타민의 유리를 억제한다. 또한 Liriodendrine에는 진통작용이 있다. 이 물질을 경구투여하면 초산으로 유도한 발 부위의 급성부종이 감소한다. Liriodendrin의 가수분해산물인 syringaresinol로 전환되어 이러한 항염증, 진통작용을 나타내는 것으로 보인다. Prickly Pear Tree Acanthopanax senticosus The roots and rhizomes of the Maxim ( Agalaceae ) are dried. The main effect of prickly ginseng is tonic action of saponin. The saponin component prevents myocardial infarction and has hypoglycemic activity in hyperglycemic animals. Prickly pear extracts inhibit skin cell-dependent anaphylaxis and release of histamine. Liriodendrine also has pain relief. Oral administration of this substance reduces acetic acid-induced acute edema in the area of the foot. It appears to have been converted to syringaresinol, a hydrolyzate of Liriodendrin, which has anti-inflammatory and analgesic effects.
산초는 초피나무 Zanhosylum piperitum DC. 또는 기타 동속 식물(산초과 Rutaceae)의 과피로 씨를 될 수 있는 대로 제거한 것이다. 산초에 들어 있는 sanshoolfb와 sanshoamid는 국소 마비 작용을 갖는 신미성 물질로 살충작용과 어독에 대한 해독 작용이 있다. α-sanshool과 β-sanshool은 두 물질 모두 거의 같은 정도의 살충 및 항균작용이 있다. Sancho Zanhosylum piperitum DC. Or as much as possible the seeds of the fruit of other congenital plants (Rtaceae). Sanshoolfb and sanshoamid, which are contained in the sancho, are microscopic substances with local paralysis action. They have insecticidal action and detoxification for fish poisoning. α-sanshool and β-sanshool have almost the same degree of insecticidal and antimicrobial activity.
비파엽은 비파 나무(Eriobotrya japonica)의 잎을 말린 것이다. 비파 잎사귀에는 포도당, 서당, 말토오스, 덱스트린, 아미그더린, 주석산 등의 성분이 함유되 어 있으며, 이 중에서 아미그더린 성분은 비타민 B17로 분류되는 특별한 성분 중의 하나다. 아미그더린이 분해해서 만들어지는 안식향산이 살균, 진통 등에 효과가 있다. Loquat leaves are dried leaves of the loquat tree (Eriobotrya japonica). Loquat leaves contain glucose, sucrose, maltose, dextrin, amithrin, tartaric acid, etc. Among them, amithrin is one of the special components classified as vitamin B17. Benzoic acid, which is produced by the breakdown of amigrin, is effective for sterilization and pain relief.
고삼은 도둑놈의 지팡이 Sophorae flavescens Ait.(콩과 Leguminosae)의 주피를 거의 벗긴 뿌리이다. 고삼 추출물은 여드름의 원인균인 Propionibacterium acnes에 강력한 항균작용을 보인다. 또한 8% 농도에서 각종 피부 진균의 발육을 억제한다. Sophoraflavone G는 Porphyromanas, Prevotella, Actinobacillus, Capnocytopaga 등에 항균작용이 있다. (+)-matrine과 (+)-oxymatrine에는 체온 강하 등의 중추억제 작용, 신경근 표본에 대한 글루탐산 차단 작용이 있다. 또한 (+)-matrine은 croton oil에 의한 귀의 염증을 현저하게 줄인다. Gosam is the thief's staff Sophorae flavescens Ait. (soybeans and Leguminosae) almost stripped roots. Ginseng extract has a strong antimicrobial activity against Propionibacterium acnes , the causative agent of acne. It also inhibits the growth of various skin fungi at 8% concentration. Sophoraflavone G has antimicrobial activity against Porphyromanas, Prevotella, Actinobacillus and Capnocytopaga. (+)-matrine and (+)-oxymatrine have central inhibitory effects, such as lowering body temperature, and glutamic acid blocking on neuromuscular specimens. (+)-Matrine also significantly reduces ear inflammation caused by croton oil.
키토올리고당은 키토산의 부분 분해물로서 물에 잘 녹고 흡수가 용이하다. 면역 증강, 항균작용, 소염 및 항염 작용, 피부 진정작용, 보습작용 등을 가지는 광범위한 고기능성 생리활성 물질이다. Chitooligosaccharides are partial decomposition products of chitosan, soluble in water and easily absorbed. It is a wide range of highly functional bioactive substances with immune enhancement, antibacterial action, anti-inflammatory and anti-inflammatory action, skin soothing action and moisturizing action.
본 발명의 화장료 조성물은 상기 6가지 한약 재료 추출물과 키토올리고당을 혼합하여 제조되는 것으로, 특히 한약재료 추출에 있어서, 단순히 종래의 열수 추출이나 용매 추출에 의해 추출물을 수득하는 것이 아니라 추출액을 다시 가열하여 그 증류액을 수집하여 수득함으로써 기존의 방법과는 차별되는 제법이라 할 수 있다. The cosmetic composition of the present invention is prepared by mixing the six herbal medicine extracts and chitooligosaccharides. Particularly, in the extraction of herbal medicines, the extract is heated again instead of simply obtaining the extract by conventional hydrothermal or solvent extraction. By collecting and obtaining the distillate, it can be said to be a manufacturing method which is different from the existing method.
특히 기존의 열수추출 시 유효성분과 함께 손상된 피부를 악화시킬 수 있는 자극 인자도 같이 추출되는 단점을 보완하기 위하여, 본 발명자 등은 열수추출 시 일정 온도 이상에서 휘발되는 증류성분을 냉각 회수하는 방법으로, 정유성분, 방향족 성분, 그리고 항산화 성분이 풍부한 열수 증류 분획을 확보하고, 이 조성물이 항산화 및 피부 진정 효과능이 있음을 확인하고 본 발명을 완성하였다.In particular, in order to compensate for the disadvantage that the stimulating factor that may worsen the damaged skin together with the active ingredient during the extraction of hot water, the present inventors, such as the method of cooling and recovering the distillation component volatilized at a predetermined temperature or more during hot water extraction, A hydrothermal distillation fraction rich in essential oils, aromatics, and antioxidants was ensured, and the composition was confirmed to have antioxidant and skin soothing effects and completed the present invention.
본 발명의 화장료 조성물의 제조방법을 구체적으로 살펴보면,Looking at the manufacturing method of the cosmetic composition of the present invention in detail,
상기 단계 i)의 열수추출은 80 내지 100℃에서 8 내지 48 시간, 바람직하게는 90 내지 95℃에서 10 내지 12 시간 추출하는 것이 바람직하다. 상기 온도 범위에서 가장 추출 효율이 높으며, 8시간 미만 추출하는 경우에는 추출 효율이 너무 낮고 48시간 이상 추출하는 것은 추출 효율에 비하여 과도하므로 경제적이지 못하다.Hot water extraction of step i) is preferably extracted for 8 to 48 hours at 80 to 100 ℃, preferably 10 to 12 hours at 90 to 95 ℃. The extraction efficiency is the highest in the above temperature range, the extraction efficiency is too low when extracted less than 8 hours and extraction more than 48 hours is not economical because it is excessive compared to the extraction efficiency.
상기 단계 ii)의 증류는 4 내지 10℃의 냉각관을 이용하여 증기를 응결함으로써 수행하게 된다. The distillation of step ii) is performed by condensing the steam using a cooling tube of 4 to 10 ℃.
또한, 본 발명의 제조방법은 상기 단계 ii) 및 iii) 사이에, 수집된 증류액을 8,000 내지 20,000 rpm에서 10 내지 50분간 원심분리하는 단계를 더 포함할 수 있다. 상기 rpm 및 시간의 범위는 증류액 중 고형분을 제거하기 위하여 적절하게 선택된 것으로, rpm의 경우는 10,000 내지 13,000 rpm이 바람직하다. 나아가, 상기 원심분리 과정은 4℃에서 30분간 수행하는 것이 바람직하다. In addition, the method of the present invention may further comprise the step of centrifuging the collected distillate at 8,000 to 20,000 rpm for 10 to 50 minutes between the steps ii) and iii). The rpm and the range of time is appropriately selected to remove solids in the distillate, in the case of rpm is preferably 10,000 to 13,000 rpm. Further, the centrifugation process is preferably performed for 30 minutes at 4 ℃.
원심분리하여 고형분을 제거 후 수득된 증류액은 키토올리고당과 혼합하여 본 발명의 화장료 조성물을 제조하게 된다. 상기 키토올리고당은 0.5%(w/v)의 저분자 키토올리고당을 이용하는 것이 좋으나 이에 한정되지 않는다. 이 키토올리고당은 전체 화장료 조성물의 20 내지 30 부피%로 포함되게 혼합하는 것이 바람직하 다. 20 부피% 미만으로 포함되는 경우에는 피부진정, 정균능, 피부 보습 등의 원하는 효과가 충분치 않고, 30 부피% 초과하여 포함되는 경우에는 제형적으로 불안하다.The distillate obtained after centrifugation to remove solids is mixed with chitooligosaccharide to prepare a cosmetic composition of the present invention. The chitooligosaccharide may be a low molecular weight chitooligosaccharide of 0.5% (w / v), but is not limited thereto. The chitooligosaccharide is preferably mixed to contain 20 to 30% by volume of the total cosmetic composition. If it is included in less than 20% by volume, the desired effect such as skin soothing, bacteriostatic, skin moisturizing is not sufficient, and when contained in more than 30% by volume is unstable formulation.
또한, 본 발명의 다른 일 측면에 따르면,In addition, according to another aspect of the present invention,
물 100 중량부에 대하여 몰약 1.5 내지 2.0 중량부, 지유 1.5 내지 2.5 중량부, 가시오가피 1.5 내지 2.5 중량부, 산초 1.5 내지 2.5 중량부, 비파엽 1.0 내지 2.0 중량부, 고삼 0.1 내지 1.0 중량부를 첨가하여 추출되는 추출물 및 키토올리고당을 포함하는 화장료 조성물로서, 상기 키토올리고당은 전체 조성물의 20 내지 30 부피%로 포함되는 화장료 조성물을 제시할 수 있다. Extract by adding 1.5 to 2.0 parts by weight, 1.5 to 2.5 parts by weight of fat milk, 1.5 to 2.5 parts by weight of oak bark, 1.5 to 2.5 parts by weight of anchovy, 1.0 to 2.0 parts by weight of non-leafed leaves, and 0.1 to 1.0 parts by weight of red ginseng. As a cosmetic composition comprising the extract and the chitooligosaccharide, the chitooligosaccharide may present a cosmetic composition comprising 20 to 30% by volume of the total composition.
본 발명의 방법에 의해 제조된 화장료 조성물을 이용하여 인간 각질형성 세포에 대해 MTT 분석한 결과, 본 발명의 화장료 조성물을 5% 처리한 경우, 무처리 (대조군)군에 비해서 106.16 ± 4.98%의 증식 정도를 보였다. 또한 1%, 0.5%, 그리고 0.1% 처리 시 각각 102.3 ± 0.74%, 106.05 ± 6.01%, 그리고 98.51 ± 6.57%로 무처리군에 비해 약간의 증식 효과를 보였다(도 1 참조). 본 결과는 본 발명의 화장료 조성물을 장기간 사용하여도 세포독성에 의한 피부 자극이 유발되지 않음을 의미하는 것이다.As a result of MTT analysis on human keratinocytes using the cosmetic composition prepared by the method of the present invention, when 5% of the cosmetic composition of the present invention was treated, 106.16 ± 4.98% proliferation was compared to the untreated (control) group. Showed degree. In addition, 10% ± 0.74%, 106.05 ± 6.01%, and 98.51 ± 6.57%, respectively, at 1%, 0.5%, and 0.1% treatment showed a slight proliferative effect compared to the untreated group (see FIG. 1). This result means that skin irritation due to cytotoxicity is not induced even after long-term use of the cosmetic composition of the present invention.
또한, DPPH를 이용한 항산화 실험에서는 무처리군과 비교하여 10% 처리 시 반응계의 DPPH 자유라디칼이 20.9 ± 2.23% 그리고 5% 처리 시 12.15 ± 1.64%, 감소됨을 확인할 수 있었다(도 2 참조). 이러한 결과는 본 발명의 화장료 조성물을 화장품 등에 응용할 경우, 5~10%의 높은 함량을 사용하여도 세포 독성이 적으면서 유의적인 항산화능으로 피부 진정 작용을 보여 줄 수 있음을 의미한다.In addition, in the antioxidation experiment using DPPH, it was confirmed that the DPPH free radicals of the reaction system were reduced by 20.9 ± 2.23% and 12.15 ± 1.64% when treated with 5% compared to the untreated group (see FIG. 2). These results mean that when the cosmetic composition of the present invention is applied to cosmetics and the like, even when using a high content of 5 ~ 10% can show a skin sedation with a significant antioxidant capacity while having less cytotoxicity.
한편, 본 발명의 화장료 조성물의 엘라스타아제 효소 활성 억제 정도를 시험한 결과에서는 본 조성물을 10% 처리시 증류수만을 사용한 대조군에 비해서 13.25% 정도의 저해 활성을 보임을 알 수 있다(도 3 참조).On the other hand, the results of testing the degree of inhibition of the elastase enzyme activity of the cosmetic composition of the present invention can be seen that the inhibitory activity of about 13.25% compared to the control group using only distilled water when the
뿐만 아니라, 본 발명의 화장료 조성물은 도 4에 나타낸 바와 같이, 한천 배지에 도말 후 배양하는 방법으로 세균 (A)과 진균 (B)의 존재를 확인한 결과, 제조 직후나 상온에서 30일간 방치 후에도 세균 (C)과 진균 (D)이 증식하지 못하였음을 확인할 수 있었다. In addition, the cosmetic composition of the present invention, as shown in Figure 4, after confirming the presence of bacteria (A) and fungi (B) by the method of culturing after plating on agar medium, bacteria even immediately after preparation or left for 30 days at room temperature (C) and fungi (D) was confirmed that the proliferation did not.
또한, 본 발명의 화장료 조성물은 패치 테스트를 이용하여 피부 자극 시험을 수행한 결과에서도 피부 자극성이 거의 없는 것으로 나타났는데(표 1 참조), 이러한 여러 결과들을 종합하면, 본 발명의 화장료 조성물은 장기간 사용시 피부 자극이나 독성이 없어 안전하면서도 뛰어난 항산화능, 피부진정작용을 가져 화장품 제조에 유용하게 사용될 수 있음을 알 수 있다. In addition, the cosmetic composition of the present invention was found to have almost no skin irritation even when performing a skin irritation test using a patch test (see Table 1) .To summarize these results, the cosmetic composition of the present invention is There is no skin irritation or toxicity, so it can be seen that it can be usefully used in the manufacture of cosmetics because it has safe and excellent antioxidant capacity and skin soothing action.
또한, 본 발명의 또 다른 측면에 따르면, 상기한 제조방법에 의하여 제조되는 조성물을 포함하는 화장품을 제시할 수 있다. 본 발명의 화장료 조성물은 외피에 사용되는 광범위한 화장품에 적용될 수 있다. 예를 들면, 수용액, 가용성 시스템, 에멀젼이나 분말, 오일, 젤, 연고, 에어로졸, 수-유 2상 시스템, 수-유-분말 3상 시스템 등의 다양한 형태를 취할 수 있다. 즉, 기초 화장품 조성물의 경우에는 세안 클린저, 화장수, 에멀젼, 크림, 젤, 엣센스, 팩, 마스크 및 기타 유형의 화장품으로서 상기한 다양한 형태에 이용될 수 있다. In addition, according to another aspect of the present invention, it is possible to present a cosmetic comprising a composition prepared by the above-described manufacturing method. The cosmetic composition of the present invention can be applied to a wide range of cosmetics used for the skin. For example, it can take various forms such as aqueous solutions, soluble systems, emulsions or powders, oils, gels, ointments, aerosols, water-oil two-phase systems, water-oil-powder three-phase systems and the like. That is, in the case of a basic cosmetic composition, it can be used in the various forms described above as a face cleanser, a lotion, an emulsion, a cream, a gel, an essence, a pack, a mask, and other types of cosmetics.
또한, 메이크업 화장품의 경우에는 광범위한 유형의 화장품, 예컨대 파운데이션으로서 사용될 수 있는 한편, 목욕용품의 경우에는 전신용 비누, 세안용 비누 등으로 사용될 수 있다. 본 발명의 조성물을 포함하는 화장품의 형태는 상기한 유형에 국한되지 않으며 본 발명의 조성물을 포함하는 한, 본 발명의 권리범위에 포함된다.In addition, in the case of makeup cosmetics can be used as a wide range of cosmetics, such as a foundation, while in the case of bath products can be used as a whole body soap, facial soap and the like. The form of the cosmetic comprising the composition of the present invention is not limited to the above-mentioned type and is included in the scope of the present invention as long as it includes the composition of the present invention.
본 발명의 화장료 조성물을 포함하는 화장품은 사용되는 용도에 따라, 그 성분으로서, 물, 알코올류, 유분, 계면활성제, 방부제, 향료, 색소, 보습제, 증점제, 수용성 고분자, 산화방지제, 킬레이트제, pH 조정제, 발포제, 비타민류, 아미노산 류, 각종 약제 및 첨가제 등을 배합할 수 있다. Cosmetics comprising the cosmetic composition of the present invention, depending on the use, as a component, water, alcohols, oils, surfactants, preservatives, flavorings, pigments, moisturizers, thickeners, water-soluble polymers, antioxidants, chelating agents, pH Modifiers, blowing agents, vitamins, amino acids, various drugs and additives can be blended.
본 발명에 의한 화장료 조성물을 포함하는 화장품은 통상의 방법에 의해 제조될 수 있으며, 하기의 제제예는 본 발명을 예시하는 것일 뿐, 이에 의해 본 발명의 내용이 제한되는 것은 아니다. Cosmetics containing a cosmetic composition according to the present invention can be prepared by a conventional method, the following formulation examples are merely to illustrate the invention, whereby the content of the present invention is not limited.
실시예 1: 화장료 조성물의 제조Example 1: Preparation of Cosmetic Composition
몰약 200g, 지유 200g, 가시오가피 200g, 산초 200g, 비파엽 15g 및 고삼 5g을 정제수에 충분히 세척한 후 물 20L를 가하여 열탕증류기에서 10 시간, 95℃로 가열하여 열수추출물을 얻었다. 이 열수 추출물을 95℃로 가열하면서, 4℃의 냉수 냉각관을 이용하여 천연물 복합체 증류액을 획득하였다. 증류액은 구체적으로 열수 추출 중 휘발되는 증기 등을 냉수 냉각관을 통과시켜 응결시키고 열탕 증류기로 회수하였다. 획득된 천연물 복합체 증류액을 12,000 rpm에서 4℃, 30분간 원심분리하여 고형분을 제거하고, 상등액을 이후의 실험에 사용하였다. Myrrh 200g, fat milk 200g, 200 g of thorny oak, 200 g of acid, 15 g of non-leaf leaves and 5 g of red ginseng were sufficiently washed in purified water, and 20 L of water was added thereto, and the mixture was heated to a boiling water distiller for 10 hours at 95 ° C. to obtain a hot water extract. While heating this hot water extract to 95 degreeC, the natural product complex distillate was obtained using the cold water cooling tube of 4 degreeC. Specifically, the distillate was condensed by passing a vapor volatilized during hot water extraction through a cold water cooling tube and recovered with a hot water still. The obtained natural complex distillate was centrifuged at 4 ° C. for 30 minutes at 12,000 rpm to remove solids, and the supernatant was used for subsequent experiments.
한편, 각각의 한약재들을 상기 방법으로 먼저 한방 추출물을 수득한 후, 최종 농도가 같도록 혼합하여도 동일한 항산화 효과를 나타내었다. On the other hand, each of the herbal medicines by the above method first to obtain the herbal extract, and then mixed to the same final concentration showed the same antioxidant effect.
수득된 한방 추출물과 0.5%(w/v)의 저분자 키토올리고당을 부피비 75 : 25의 비율로 혼합하여 본 발명의 화장료 조성물을 제조하였다.The herbal extract obtained and 0.5% (w / v) of low molecular weight chitooligosaccharide were mixed at a volume ratio of 75:25 to prepare a cosmetic composition of the present invention.
시험예 1: 인간 각질형성 세포 배양Test Example 1: Human keratinocyte cell culture
인간 각질형성 세포인 HaCaT 세포주는 본 연구를 위하여 37℃, 5% CO2 배양기에서 배양되었다. 배양 용기의 85 ~ 90%의 면적 만큼의 배양도를 보이면, 트립신 처리로 세포를 탈착시켜 계수 후, 5 × 103 cells/Cm2으로 계대 배양하였다. 세포의 배양에는 10% 우태아혈청 (FBS, GIBCO, Cat. No., 26140-079, USA)과 100 U/ml 페닐실린 및 100 ug/ml 스트렙토마이신이 첨가된 Delbecco's Modified Eagle Medium (DMEM, GIBCO, Cat. No. 11995-065, USA)을 사용하였다. 계대 배양을 위하여 75 T-flask (NUNC, Cat. No. 156499, Danmark)가 사용되었으며, 세포 독성 시험을 위해서는 24 well plate (NUNC, Cat. No., 142475, Danmark)가 사용되었다.HaCaT cell line, a human keratinocyte, was cultured in a 37 ° C., 5% CO 2 incubator for this study. When the degree of culture as much as 85 to 90% of the culture vessel was shown, the cells were detached by trypsin treatment, counted, and subcultured at 5 × 10 3 cells / Cm 2 . Cells were cultured with 10% fetal calf serum (FBS, GIBCO, Cat. No., 26140-079, USA) and Delbecco's Modified Eagle Medium (DMEM, GIBCO) with 100 U / ml phenylcillin and 100 ug / ml streptomycin. , Cat. No. 11995-065, USA). 75 T-flask (NUNC, Cat. No. 156499, Danmark) was used for subculture, and 24 well plate (NUNC, Cat. No., 142475, Danmark) was used for cytotoxicity test.
시험예 2: MTT를 이용한 세포 독성 시험Test Example 2: Cytotoxicity Test Using MTT
화장료 조성물의 장기간 사용시 유발될 수 있는 피부 자극에 대한 간접적 평가로 인간 유래의 각질형성 세포주 HaCaT을 이용한 MTT 시험을 수행하였다. 시험예 1에서 설명된 방식으로 배양되는 인간 각질형성 세포를 24 well plate에 5 × 103 cells/well 씩 동일하게 heamacytometer를 이용하여 계수한 후 분주하였다. 10% FBS를 함유하는 DMEM에서 48시간 배양하여 배양용기 표면적의 25~30% 만큼 자라면, 본 발명의 화장료 조성물이 0.1~10% 함유된 FBS-free DMEM으로 교체하여 24시간 더 배양하였다. 배양 후 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT, Sigma M5655, USA) 용액 (2.5 mg/ml)을 50 ul 첨가하고 3시간 추가 배양하였다. 그 후, 세포 배양액을 전부 버리고, 200 ul의 dimethyl sulfoxide (DMSO, Sigma D2650, USA)를 각 well 당 200ul 처리하여 교반한 후, 100 ul 씩 96 well로 취하여 ELISA(Enzyme-Linked Immunosorbent Assay)로 570 nm에서 흡광도를 측정하였다. 세포 독성 정도는 순수한 물을 사용한 대조군의 흡광 강도를 기준으로 백분율로 표시하였다. 그 결과를 도 1에 나타내었다. The MTT test using the human-derived keratinocyte cell line HaCaT was performed as an indirect assessment of skin irritation that may be caused by long-term use of the cosmetic composition. Human keratinocytes cultured in the manner described in Test Example 1 were counted using a heamacytometer at 5 x 10 3 cells / well in 24 well plates and then aliquoted. After 48 hours of incubation in DMEM containing 10% FBS to grow as much as 25-30% of the surface of the culture vessel, the cosmetic composition of the present invention was replaced with FBS-free DMEM containing 0.1-10% and incubated for 24 hours. After incubation, 50 ul of a 3- (4,5-dimethylthiazol-2-yl) -2,5-diphenyl tetrazolium bromide (MTT, Sigma M5655, USA) solution (2.5 mg / ml) was added thereto, followed by further incubation for 3 hours. Subsequently, discard the cell culture medium, and 200 ul of dimethyl sulfoxide (DMSO, Sigma D2650, USA) was treated with 200 ul for each well, followed by stirring. Absorbance was measured at nm. The degree of cytotoxicity was expressed as a percentage based on the absorbance intensity of the control group using pure water. The results are shown in FIG.
5% 처리한 결과 무처리 (대조군)군에 비해서 106.16 ± 4.98%의 증식 정도를 보였다. 또한 1%, 0.5%, 그리고 0.1% 처리 시 각각 102.3 ± 0.74%, 106.05 ± 6.01%, 그리고 98.51 ± 6.57%로 무처리군에 비해 약간의 증식 효과를 보였다. 본 결과는 본 발명의 화장료 조성물을 장기간 사용하여도 세포독성에 의한 피부 자극이 유발되지 않음을 의미하는 것이다.The 5% treatment resulted in 106.16 ± 4.98% proliferation compared to the untreated (control) group. In addition, 102.3 ± 0.74%, 106.05 ± 6.01%, and 98.51 ± 6.57%, respectively, at 1%, 0.5%, and 0.1% treatment showed a slight proliferative effect. This result means that skin irritation due to cytotoxicity is not induced even after long-term use of the cosmetic composition of the present invention.
시험예 3: DPPH를 이용한 항산화 시험Test Example 3: Antioxidant Test Using DPPH
본 발명의 화장료 조성물의 항산화능 정도를 조사하기 위하여, 에탄올 내에서 자유라디칼을 생성하는 화합물 1,1-diphenyl-2-picryl hydrazyl (DPPH, Sigma D9132-1G, USA)과 본 발명의 화장료 조성물을 일정 비율로 혼합하여 생성된 자유라디칼의 양이 어느 정도 감소하는지를 확인하였다. In order to investigate the degree of antioxidant activity of the cosmetic composition of the present invention, the
간략하게는, 에탄올 0.4 ml에 에탄올로 제조된 0.1 mM DPPH 용액 0.5 ml 및 0.5%~10%의 화장료 조성물을 함유하는 시험물질 0.1 ml을 첨가한다. 10초간 강하게 vortexing 하고, 냉암소에서 30분간 보관한다. ELISA를 이용하여 517 nm에서 흡광도를 측정한다. 항산화능의 정도는 순수한 물을 사용한 대조군의 흡광 강도를 기준으로 백분율로 표시하고 도 2에 그 결과를 나타내었다. Briefly, 0.1 ml of test substance containing 0.5 ml of 0.1 mM DPPH solution made from ethanol and 0.5% to 10% of the cosmetic composition is added to 0.4 ml of ethanol. Vortex strongly for 10 seconds and store in a cool dark place for 30 minutes. Absorbance is measured at 517 nm using ELISA. The degree of antioxidant activity was expressed as a percentage based on the absorbance intensity of the control group using pure water and the results are shown in FIG.
도 2에 나타난 바와 같이, 무처리군과 비교하여 10% 처리 시 반응계의 DPPH 자유라디칼이 20.9 ± 2.23%, 5% 처리 시 12.15 ± 1.64% 감소함을 확인할 수 있었다. 그러나 0.5% 처리 시는 대조군에 비하여 유의적 차이를 보이지는 않았다. 이러한 결과는 본 발명의 화장료 조성물을 5~10%의 높은 함량으로 사용하여도 세포 독성이 적으면서 유의적인 항산화능으로 피부 진정 작용을 나타낼 수 있음을 의미한다.As shown in FIG. 2, the DPPH free radicals of the reaction system were reduced by 20.9 ± 2.23% and 12.15 ± 1.64% when treated by 5% compared to the non-treated group. However, 0.5% treatment did not show a significant difference compared to the control. These results indicate that even when the cosmetic composition of the present invention is used at a high content of 5 to 10%, the cytotoxicity can be exhibited with significant antioxidant capacity while having less cytotoxicity.
시험예 4: 엘라스타아제(Elastase) 효소 활성 억제 시험Test Example 4: Elastase enzyme activity inhibition test
엘라스타아제는 과도한 UV 및 환경 스트레스에 노출되거나 정상적인 노화에 의해서 발현이 촉진되어 피부 주름을 형성하는 주요한 요인으로 알려져 있다. 본 발명의 화장료 조성물이 엘라스타아제 효소 활성 억제능을 갖는지 확인하기 위하여 96 well 배양접시에 0.1M의 Sodium phosphate(pH 7.5)/0.5M NaCl의 반응 버퍼 180ul 넣어준 후 여기에 엘라스타아제를 20ul 첨가한다. 본 발명의 조성물 10%를 25ul 첨가한 후 suc-AlaAlaAla를 25ul 첨가하고 405nm에서 흡광도를 측정한다. 엘라스타아제 효소 활성 억제 정도는 순수한 물을 사용한 대조군의 흡광 강도를 기준으로 백분율로 표시하였다. 그 결과를 도 3에 나타낸다. 본 조성물을 10% 처리시 증류수만을 사용한 대조군에 비해서 13.25% 정도의 저해 활성을 보였다. Elastase is known to be a major factor in the formation of skin wrinkles by being exposed to excessive UV and environmental stress or by the expression of normal aging. In order to confirm that the cosmetic composition of the present invention has the ability to inhibit the enzyme activity of elastase, a reaction buffer of 0.1 M of sodium phosphate (pH 7.5) /0.5M NaCl was added to a 96 well culture dish, and then 20 ul of elastase was added thereto. do. After adding 25ul of 10% of the composition of the present invention, 25ul of suc-AlaAlaAla is added and the absorbance is measured at 405 nm. The degree of inhibition of elastase enzyme activity was expressed as a percentage based on the absorbance intensity of the control group using pure water. The result is shown in FIG. When the composition was treated with 10%, the inhibitory activity was about 13.25% compared to the control using only distilled water.
시험예 5: 잔존 생균 시험을 통한 정균능Test Example 5: The bacteriostatic ability through the remaining live bacteria test
레이져 박피 후의 피부는 많이 약해져 있기 때문에 비정상적인 미생물 천이가 유발되며 이는 레이져 박피 후의 2차 감염 등의 문제가 일어날 수 있다. 본 발명의 화장료 조성물이 방부제 처리 없이 미생물이 생존하지 않게 하는 정균능을 가지는지를 확인하였다. 본 발명의 화장료 조성물 내 발생 가능한 생균의 수를 확인하기 위하여 조성물을 제조한 직후 그리고 30일간 상온에서 방치한 후 생균수 확인 시험을 실시하였다. 구체적으로, 본 발명의 조성물 원액 0.1 ml을 레틴 한천배지 (Difco, USA)에 도말하고 30℃에서 48시간 배양하여 세균의 존재를 확인하였으며, 0.1ml을 사브로우드 덱스트로즈 한천배지 (Difco, USA)에 도말하고 25℃에서 72시간 배양하여 진균의 존재를 확인하였다.Since the skin after laser dermabrasion is much weakened, abnormal microbial transition is caused, which may cause problems such as secondary infection after laser dermabrasion. It was confirmed whether the cosmetic composition of the present invention had bacteriostatic ability to prevent microorganisms from living without preservative treatment. In order to confirm the number of viable bacteria in the cosmetic composition of the present invention, immediately after the composition was prepared and left for 30 days at room temperature, a viable cell number identification test was performed. Specifically, 0.1 ml of the composition stock solution of the present invention was smeared on a retinal agar medium (Difco, USA) and incubated at 30 ° C. for 48 hours to confirm the presence of bacteria, and 0.1 ml of Sabrowood dextrose agar medium (Difco, USA) and incubated for 72 hours at 25 ℃ to confirm the presence of fungi.
도 4에 나타난 바와 같이, 세균 (A)과 진균 (B)의 존재를, 본 발명의 화장료 조성물을 제조 직후 한천 배지에 도말 후 배양하는 방법으로 확인한 결과 생균이 존재하지 않았으며, 상온에서 30일간 방치 후에도 세균 (C)과 진균 (D)이 증식하지 못하였음을 확인할 수 있었다. As shown in Figure 4, the presence of bacteria (A) and fungi (B) was confirmed by the method of culturing after plating on the agar medium immediately after the preparation of the cosmetic composition of the present invention, there was no live bacteria, 30 days at room temperature After standing, it was confirmed that bacteria (C) and fungi (D) did not proliferate.
따라서, 본 발명의 조성물은 상온에서 장기간 보관에도 방부제의 첨가 없이 미생물의 천이를 억제하는 정균능을 가지기 때문에 손상된 피부의 2차 감염을 억제하여 염증을 방지함으로써 피부진정 효과를 가능하게 할 수 있다.Therefore, the composition of the present invention has a bacteriostatic ability to inhibit the transition of microorganisms without the addition of preservatives even at long-term storage at room temperature, thereby enabling the skin soothing effect by preventing secondary infection of the damaged skin and preventing inflammation.
시험예 6: 피부 자극 실험Test Example 6: Skin Irritation Experiment
대부분의 한방 추출물의 경우 일반 화학제품들에 비해 피부 자극이 적은 것은 사실이나 피부 유해물질들이 제대로 제거되지 않을 경우 피부 트러블을 유발할 수 있는 문제가 있는 바, 본 발명의 화장료 조성물의 피부 자극 정도를 측정하기 위해 11명의 피험자들을 대상으로 패치 테스트(patch test)를 실시하였다. Most herbal extracts have less skin irritation than general chemicals, but there is a problem that may cause skin trouble if the skin harmful substances are not properly removed, thereby measuring the degree of skin irritation of the cosmetic composition of the present invention. In order to do this, a patch test was conducted on 11 subjects.
본 발명의 조성물 및 대조군을 100ul 함유하는 패치를 피험자의 팔 안쪽 깨끗한 부위에 부착하고 48시간 후에 흐르는 물로 씻어낸 후 30분 후의 자극 정도를 판정하였다. 음성대조군은 순수한 물을 사용하였으며, 양성대조군은 5%의 SLS (Sodium Laureth Sulfate)를 사용하였다. 피부 반응의 평가를 자극 수치를 5단계로 나누어 판정한 결과, 본 조성물의 피부 자극성은 음성대조군에서 4.5, 양성대조군에서 38.6, 본 발명의 조성물은 9.1로 피부 자극성이 거의 존재하지 않음을 확인하였다.A patch containing 100ul of the composition and the control of the present invention was attached to a clean area inside the subject's arm and washed 48 hours later with running water to determine the degree of stimulation after 30 minutes. The negative control group was pure water, and the positive control group was 5% sodium laureth sulfate. As a result of evaluating the skin response by dividing the stimulus value into five stages, it was confirmed that the skin irritation of the present composition was 4.5 in the negative control group, 38.6 in the positive control group, and 9.1 of the composition of the present invention.
* 피부 자극 평균 정도(%) :* Average skin irritation (%):
{(4자극 수치×해당피검자수)+(3자극 수치×해당피검자수)+(2자극 수치×해당피검자수)+(1자극 수치×해당피검자수)+(0자극 수치×해당피검자수)}×100/최고자극수치(4)×전체피검자수){(4 Stimulus Number × Number of Subjects) + (3 Stimulus Number × Number of Subjects) + (2 Stimulus Number × Number of Subjects) + (1 Stimulus Number × Number of Subjects) + (0 Stimulus Number × Number of Subjects) } × 100 / maximum stimulus value (4) × all subjects)
* 자극성 판정 : * Irritation determination:
1(10 이하, 최소 자극), 2(10-20, 온화한 자극) 3(20-30, 보통 자극), 4(30 이상, 심한 자극)1 (less than 10, minimal stimulation), 2 (10-20, mild stimulation) 3 (20-30, moderate stimulation), 4 (more than 30, severe stimulation)
제제예 1 : 화장수(스킨, 로션)의 제조Formulation Example 1 Preparation of Lotion (Skin, Lotion)
하기와 같이 본 발명의 조성물을 함유하는 화장수(스킨, 로션)을 통상의 방법에 따라 제조하였다.A lotion (skin, lotion) containing the composition of the present invention as described below was prepared according to a conventional method.
본 발명의 조성물 10(단위; 중량%)Composition 10 (Unit; Weight%) of the Invention
글리세린 3.0Glycerin 3.0
부틸렌글리콜 2.0Butylene Glycol 2.0
프로필렌글리콜 2.0Propylene Glycol 2.0
폴리옥시에틸렌 경화피마자유 1.0Polyoxyethylene Cured Castor Oil 1.0
에탄올 10.0Ethanol 10.0
트리에탄올아민 0.1Triethanolamine 0.1
방부제 미량Preservative traces
향료 미량A small amount of spices
색소 미량A small amount of pigment
정제수 잔부Purified water balance
제제예 2: 맛사지 크림의 제조 Formulation Example 2: Preparation of Massage Cream
맛사지 크림을 통상의 방법에 따라 제조하였다. Massage creams were prepared according to conventional methods.
카르복시비닐폴리머 0.45(단위; 중량%)Carboxy vinyl polymer 0.45 (unit; weight%)
트리에탄올아민 0.9Triethanolamine 0.9
글리세릴스테아레이트 1.5Glyceryl Stearate 1.5
세틸알콜 2.0Cetyl Alcohol 2.0
피이지-30 글리세릴코코에이트 1.0Fiji-30 Glyceryl Cocoate 1.0
피이지-80 글리세필코코에이트 1.0Fiji-80 Glyceryl Cocoate 1.0
소듐코코암포프로피오네이트 4.0Sodium coco ampopropionate 4.0
본 말명의 조성물 3.0Composition 3.0 of the present term
방부제 적량Preservative
향료 적량Spices
색소 적량Pigment amount
정제수 잔부Purified water balance
제제예 3: 비누의 제조 Formulation Example 3 Preparation of Soap
본 발명의 조성물을 함유한 비누를 통상의 방법에 따라 제조하였다.Soaps containing the compositions of the present invention were prepared according to conventional methods.
야자유지방산 1.5(단위; 중량%)Palm oil fatty acid 1.5 (unit; weight%)
이산화티탄 0.5Titanium Dioxide 0.5
에틸렌디아민테트라아세트산디나트륨 0.15Ethylenediaminetetraacetic acid disodium 0.15
본 발명의 조성물 0.3Composition 0.3 of the present invention
방부제 적량Preservative
향료 적량Spices
색소 적량Pigment amount
비누칩베이스 잔부Soap Chip Base Balance
상기에서 살펴본 바와 같이, 본 발명의 제조방법에 의하면, 세포 독성이 없고, 항산화능을 가지며, 엘라스타아제 활성을 억제할 뿐만 아니라 정균능을 가지면서도 피부 자극이 없는 한방 화장료 조성물을 정제된 상태로 간단하게 제조할 수 있다. As described above, according to the preparation method of the present invention, the herbal cosmetic composition having no cytotoxicity, having antioxidant capacity, inhibiting elastase activity, and having bacteriostatic ability but no skin irritation in a purified state It can be manufactured simply.
Claims (9)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020070041426A KR100861415B1 (en) | 2007-04-27 | 2007-04-27 | Method of preparing cosmetics composition and cosmetics for anti-oxidation and skin-calming, prepared therefrom |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020070041426A KR100861415B1 (en) | 2007-04-27 | 2007-04-27 | Method of preparing cosmetics composition and cosmetics for anti-oxidation and skin-calming, prepared therefrom |
Publications (1)
Publication Number | Publication Date |
---|---|
KR100861415B1 true KR100861415B1 (en) | 2008-10-07 |
Family
ID=40152651
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020070041426A KR100861415B1 (en) | 2007-04-27 | 2007-04-27 | Method of preparing cosmetics composition and cosmetics for anti-oxidation and skin-calming, prepared therefrom |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR100861415B1 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20180053019A (en) * | 2016-11-11 | 2018-05-21 | 주식회사 바이오웨이 | Cosmetic composition having safety and superior moisturizing effect for skin |
CN115337232A (en) * | 2021-05-13 | 2022-11-15 | Ahava-死海实验室有限公司 | Anti-glycation compositions |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR930012027A (en) * | 1991-12-13 | 1993-07-20 | 한동근 | Acne Treatment Composition |
KR970073571A (en) * | 1996-05-07 | 1997-12-10 | 이능희 | A cosmetic composition comprising a complex of chitosan oligosaccharide and amino acid |
-
2007
- 2007-04-27 KR KR1020070041426A patent/KR100861415B1/en active IP Right Grant
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR930012027A (en) * | 1991-12-13 | 1993-07-20 | 한동근 | Acne Treatment Composition |
KR970073571A (en) * | 1996-05-07 | 1997-12-10 | 이능희 | A cosmetic composition comprising a complex of chitosan oligosaccharide and amino acid |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20180053019A (en) * | 2016-11-11 | 2018-05-21 | 주식회사 바이오웨이 | Cosmetic composition having safety and superior moisturizing effect for skin |
KR101986364B1 (en) | 2016-11-11 | 2019-06-07 | 주식회사 바이오웨이 | Cosmetic composition having safety and superior moisturizing effect for skin |
CN115337232A (en) * | 2021-05-13 | 2022-11-15 | Ahava-死海实验室有限公司 | Anti-glycation compositions |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN105616283B (en) | A kind of plant essence restorative facial cream | |
CN105434310B (en) | Application of periplaneta americana active ingredient extract in preparation of cosmetics | |
KR20100010316A (en) | Cosmetic composition for preventing skin aging | |
KR102271001B1 (en) | Method for manufacturing chaga extract using high voltage pulsed electric field treatment and cosmetic composition comprising the same | |
KR20200088074A (en) | Skin external composition comprising centella asiatica extract and papaver rhoeas extract | |
CN107184448A (en) | A kind of acne eliminating cream that there is prevention pockmark to generate | |
KR100564108B1 (en) | Cosmetic composition comprising plant extract having anti-aging effect | |
CN108498390B (en) | Tibetan herbal extract for treating acne and preparation method and application thereof | |
CN109453094B (en) | Mosquito-repelling and itching-relieving composition and skin care product containing composition | |
KR102300581B1 (en) | Compositions for improving skin conditions comprising plant extracts or fractions thereof | |
CN103494737A (en) | Cosmetic preparation using ginger flower as anti-ageing and skin-protecting factor and preparation method of cosmetic preparation | |
CN111743826A (en) | Freckle-removing, wrinkle-resisting and moisturizing emulsion | |
KR20100124132A (en) | Anti-wrinkle cosmetic composition containing oriental herb extract treated by enzyme and its extraction method | |
CN108938511B (en) | Composition of natural plant extracts and application of composition in skin moisturizing and acne removing products | |
KR100861415B1 (en) | Method of preparing cosmetics composition and cosmetics for anti-oxidation and skin-calming, prepared therefrom | |
CN112402308A (en) | Multi-effect relieving moisturizing lotion and preparation method thereof | |
KR102226179B1 (en) | Cosmetic Compositions for Anti-aging Comprising Extracts of Plants | |
KR20150112103A (en) | Compositions for improving skin conditions comprising plant extracts or fractions thereof | |
JP7338842B2 (en) | wrinkle-improving composition and wrinkle-improving skin cosmetic | |
KR100971655B1 (en) | Cosmetic composition with the anti-oxidant, anti-inflammatory and anti-wrinkled effect | |
KR20210072966A (en) | Nanocapsule composition for skin moisturizing or skin inflammatory improvement comprsing encapsulated centella and calamine | |
CN110613663A (en) | Skin repairing composition, skin care product and preparation method thereof | |
CN107550847B (en) | Active skin care composition and application thereof | |
CN112638357A (en) | Composition for promoting differentiation or proliferation of human adipose-derived stem cells | |
CN115414308A (en) | Acne removing composition as well as preparation method and application thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20120823 Year of fee payment: 5 |
|
FPAY | Annual fee payment |
Payment date: 20130820 Year of fee payment: 6 |
|
FPAY | Annual fee payment |
Payment date: 20140805 Year of fee payment: 7 |
|
FPAY | Annual fee payment |
Payment date: 20150818 Year of fee payment: 8 |
|
FPAY | Annual fee payment |
Payment date: 20160622 Year of fee payment: 9 |
|
FPAY | Annual fee payment |
Payment date: 20170106 Year of fee payment: 10 |
|
FPAY | Annual fee payment |
Payment date: 20190222 Year of fee payment: 12 |
|
FPAY | Annual fee payment |
Payment date: 20200303 Year of fee payment: 13 |